KR100913471B1 - 항신생물제로서의 티오펜- 및 티아졸술폰아미드 - Google Patents

항신생물제로서의 티오펜- 및 티아졸술폰아미드 Download PDF

Info

Publication number
KR100913471B1
KR100913471B1 KR1020047006058A KR20047006058A KR100913471B1 KR 100913471 B1 KR100913471 B1 KR 100913471B1 KR 1020047006058 A KR1020047006058 A KR 1020047006058A KR 20047006058 A KR20047006058 A KR 20047006058A KR 100913471 B1 KR100913471 B1 KR 100913471B1
Authority
KR
South Korea
Prior art keywords
mmol
sulfonamide
added
solution
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047006058A
Other languages
English (en)
Korean (ko)
Other versions
KR20040062583A (ko
Inventor
알폰소 데디오스
코라 수 그로스만
필립 아서 힙스킨드
호-쉔 린
카렌 린 롭
베아뜨리 로뻬데우랄데가르멘디아
조세 에두아르도 로페즈
메리 마가렛 마더
마이클 엔리코 리체트
추안 시
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20040062583A publication Critical patent/KR20040062583A/ko
Application granted granted Critical
Publication of KR100913471B1 publication Critical patent/KR100913471B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020047006058A 2001-10-25 2002-10-15 항신생물제로서의 티오펜- 및 티아졸술폰아미드 Expired - Fee Related KR100913471B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25
US60/352,012 2001-10-25
PCT/US2002/031568 WO2003035629A1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Publications (2)

Publication Number Publication Date
KR20040062583A KR20040062583A (ko) 2004-07-07
KR100913471B1 true KR100913471B1 (ko) 2009-08-25

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047006058A Expired - Fee Related KR100913471B1 (ko) 2001-10-25 2002-10-15 항신생물제로서의 티오펜- 및 티아졸술폰아미드

Country Status (33)

Country Link
US (2) US7084170B2 (https=)
EP (1) EP1442030B1 (https=)
JP (1) JP4464681B2 (https=)
KR (1) KR100913471B1 (https=)
CN (1) CN1298709C (https=)
AR (1) AR037248A1 (https=)
AT (1) ATE338033T1 (https=)
AU (1) AU2002334817B2 (https=)
BR (1) BR0212386A (https=)
CA (1) CA2463300C (https=)
CY (1) CY1106247T1 (https=)
DE (1) DE60214413T2 (https=)
DK (1) DK1442030T3 (https=)
EA (1) EA006081B1 (https=)
EC (1) ECSP045078A (https=)
EG (1) EG26021A (https=)
ES (1) ES2269816T3 (https=)
HR (1) HRP20040371B1 (https=)
HU (1) HUP0401638A3 (https=)
IL (2) IL160851A0 (https=)
MX (1) MXPA04003886A (https=)
MY (1) MY130718A (https=)
NO (1) NO20041316L (https=)
NZ (1) NZ531136A (https=)
PE (1) PE20030574A1 (https=)
PL (1) PL208083B1 (https=)
PT (1) PT1442030E (https=)
SI (1) SI1442030T1 (https=)
SV (1) SV2004001367A (https=)
TW (1) TWI281916B (https=)
UA (1) UA75716C2 (https=)
WO (1) WO2003035629A1 (https=)
ZA (1) ZA200403089B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
AU2003249683A1 (en) * 2002-06-06 2003-12-22 Smithkline Beecham Corporation Nf-:b inhibitors
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
EP2364699A1 (en) * 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
PL1859793T3 (pl) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
JPWO2006090928A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の血管新生阻害物質との新規併用
BRPI0610283A2 (pt) * 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
US7939532B2 (en) * 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
US7879884B2 (en) 2007-05-16 2011-02-01 Hoffmann-La Roche Inc. Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团（天津）股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法
EP4724106A1 (en) * 2023-06-07 2026-04-15 Kræftens bekæmpelse Protacs and hyt-pd molecules for targeted protein degradation of dcaf15 and their use in the treatment of amyloidosis
WO2025031361A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物作为制备治疗癌症药物的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment
US20010008898A1 (en) 2000-01-11 2001-07-19 Tsuyoshi Tomiyama Ether and amide compounds and preparation of thereof as antidiadetics.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
IL98784A0 (en) 1990-07-17 1992-07-15 Lilly Co Eli Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them
WO1998001440A2 (en) * 1996-07-05 1998-01-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment
US20010008898A1 (en) 2000-01-11 2001-07-19 Tsuyoshi Tomiyama Ether and amide compounds and preparation of thereof as antidiadetics.

Also Published As

Publication number Publication date
EG26021A (en) 2012-12-10
KR20040062583A (ko) 2004-07-07
DE60214413T2 (de) 2007-03-08
MY130718A (en) 2007-07-31
CY1106247T1 (el) 2011-06-08
CA2463300C (en) 2011-07-19
HUP0401638A3 (en) 2012-09-28
EP1442030B1 (en) 2006-08-30
IL160851A0 (en) 2004-08-31
JP4464681B2 (ja) 2010-05-19
TWI281916B (en) 2007-06-01
ES2269816T3 (es) 2007-04-01
US20060223871A1 (en) 2006-10-05
UA75716C2 (en) 2006-05-15
IL160851A (en) 2009-11-18
US7084170B2 (en) 2006-08-01
NZ531136A (en) 2006-08-31
EP1442030A1 (en) 2004-08-04
ZA200403089B (en) 2005-04-22
CN1575286A (zh) 2005-02-02
EA200400582A1 (ru) 2004-08-26
CN1298709C (zh) 2007-02-07
US20040198784A1 (en) 2004-10-07
PL368234A1 (en) 2005-03-21
HRP20040371A2 (en) 2004-08-31
HRP20040371B1 (en) 2012-07-31
DE60214413D1 (de) 2006-10-12
WO2003035629A1 (en) 2003-05-01
EA006081B1 (ru) 2005-08-25
NO20041316L (no) 2004-03-30
BR0212386A (pt) 2004-07-27
SV2004001367A (es) 2004-02-24
PE20030574A1 (es) 2003-07-03
MXPA04003886A (es) 2004-07-08
JP2005511547A (ja) 2005-04-28
HK1068337A1 (en) 2005-04-29
ATE338033T1 (de) 2006-09-15
DK1442030T3 (da) 2006-12-27
AU2002334817B2 (en) 2008-02-21
PL208083B1 (pl) 2011-03-31
SI1442030T1 (sl) 2006-12-31
ECSP045078A (es) 2004-06-28
PT1442030E (pt) 2006-12-29
CA2463300A1 (en) 2003-05-01
US7250430B2 (en) 2007-07-31
HUP0401638A2 (hu) 2004-11-29
AR037248A1 (es) 2004-11-03

Similar Documents

Publication Publication Date Title
KR100913471B1 (ko) 항신생물제로서의 티오펜- 및 티아졸술폰아미드
AU2002334817A1 (en) Thiopene- and Thiazolesulfonamides as Antineoplastic Agents
JP4167173B2 (ja) 抗腫瘍剤としての使用のためのベンゾイルスルホンアミドおよびスルホンベンズアミジン
US6964975B2 (en) Isoxazole and thiazole compounds and use thereof as medicine
US20090118323A1 (en) Antitumor benzoylsulfonamides
EP2324006B1 (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
JP2004530709A5 (https=)
US20230192650A1 (en) Novel acid secretion inhibitor and use thereof
CS237346B2 (en) Processing of racemic or opticaly active 5-substituted oxazolidine-2,4-dione
HK1068337B (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents
KR20220162116A (ko) Aimp2-dx2와 kras의 결합을 억제하는 신규 화합물 및 이의 용도

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130815

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130815